1. Bruton’s tyrosine kinase inhibitor pirtobrutinib showed efficacy in the treatment of relapsed or refractory B-cell malignancies such as chronic ...
1. Ibrutinib, an inhibitor of Bruton’s tyrosine kinase, produced a response in 90.5% of patients with Waldenström’s macroglobulinemia. 2. Patient ...
Originally published by Harvard Health. What Is It? Waldenström macroglobulinemia (WM) is a rare, slow-growing cancer. It is a form of ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.